Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – Investment analysts at Jefferies Financial Group issued their Q3 2020 earnings estimates for shares of Harmony Biosciences in a note issued to investors on Monday, September 14th. Jefferies Financial Group analyst C. Howerton forecasts that the company will post earnings per share of $0.12 for the quarter. Jefferies Financial Group currently has a “Buy” rating and a $51.00 target price on the stock. Jefferies Financial Group also issued estimates for Harmony Biosciences’ Q4 2020 earnings at $0.32 EPS, FY2020 earnings at ($0.59) EPS, FY2021 earnings at $1.19 EPS, FY2022 earnings at $3.62 EPS, FY2023 earnings at $4.14 EPS and FY2024 earnings at $6.40 EPS.
A number of other research analysts also recently weighed in on HRMY. Piper Sandler began coverage on Harmony Biosciences in a report on Monday. They set an “overweight” rating and a $61.00 target price on the stock. Goldman Sachs Group started coverage on Harmony Biosciences in a report on Sunday. They set a “neutral” rating and a $43.00 target price on the stock.
In related news, major shareholder Holdings A/S Novo purchased 132,503 shares of the company’s stock in a transaction dated Friday, August 21st. The shares were purchased at an average cost of $24.00 per share, with a total value of $3,180,072.00. Following the transaction, the insider now directly owns 4,277,300 shares in the company, valued at approximately $102,655,200. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, Director Jack Nielsen purchased 3,057 shares of the company’s stock in a transaction dated Monday, August 24th. The stock was bought at an average cost of $34.30 per share, for a total transaction of $104,855.10. The disclosure for this purchase can be found here. Over the last three months, insiders bought 138,296 shares of company stock worth $3,380,687.
About Harmony Biosciences
Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients living with rare neurological disorders. Its lead product includes WAKIX (pitolisant) for the treatment of pediatric patients suffering from narcolepsy. Harmony Biosciences Holdings, Inc was formerly known as Harmony Biosciences II, Inc and changed its name to Harmony Biosciences Holdings, Inc in February 2020.
Read More: Bond
Receive News & Ratings for Harmony Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harmony Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.